×
About 12,465 results

JAK Inhibitor Improves Symptoms, Anemia in Myelofibrosis
https://www.medpagetoday.com/hematologyoncology/othercancers/102883

Jan 30th, 2023 - Myelofibrosis treatment with the Janus kinase (JAK) inhibitor momelotinib resulted in clinically significant improvements in symptoms and spleen response compared with danazol for symptomatic, JAK inhibitor-exposed patients with anemia and intermediate- or high-risk disease, the phase III MOMENTUM trial showed. A significantly greater proportion of patients in the momelotinib group reported a ≥...

FDA Greenlights First Drug for ESR1-Mutated Breast Cancer
https://www.medpagetoday.com/hematologyoncology/breastcancer/102880

Jan 30th, 2023 - The FDA approved the selective estrogen receptor (ER) degrader elacestrant (Orserdu) for the treatment of postmenopausal women or adult men with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy. The FDA also approved the Guardant360 CDx assay as a companion diagnostic test to identify patients...

Reversible BTK Inhibitor Gets FDA Nod for Mantle Cell Lymphoma
https://www.medpagetoday.com/hematologyoncology/lymphoma/102874

Jan 30th, 2023 - The FDA has granted accelerated approval to pirtobrutinib (Jaypirca), a non-covalent or reversible Bruton's tyrosine kinase (BTK) inhibitor, for the treatment of relapsed or refractory mantle cell lymphoma (MCL) after at least two prior lines of systemic therapy, including a BTK inhibitor. Pirtobrutinib is the first BTK inhibitor of any kind specifically approved for patients with MCL that has ...

Analysis of ctDNA Pinpoints Responders to Second-Line GIST Therapy
https://www.medpagetoday.com/hematologyoncology/othercancers/102862

Jan 27th, 2023 - Circulating tumor DNA (ctDNA) analysis of KIT mutational status may be able to guide second-line treatment in patients with imatinib-resistant gastrointestinal stromal tumors (GIST), according to an exploratory analysis from the INTRIGUE trial. Specifically, patients with KIT exon 11 plus 17/18 (activation loop) mutations had superior responses and better survival outcomes with ripretinib (Qinl...

ODAC to Review Lymphoma Drug; Tobacco Control; Artificial Skin Aids Cancer Studies
https://www.medpagetoday.com/hematologyoncology/lymphoma/102854

Jan 27th, 2023 - The FDA announced that the Oncologic Drugs Advisory Committee (ODAC) will meet March 9 to review the accelerated approval of polatuzumab vedotin (Polivy) plus rituximab (Rituxan) and chemotherapy for untreated diffuse large B-cell lymphoma. Janssen and Legend Biotech announced early termination of a phase III trial after an interim analysis showed that ciltacabtagene autoleucel (cilta-cel, Carv...

FDA OKs Adjuvant Pembrolizumab for NSCLC
https://www.medpagetoday.com/hematologyoncology/lungcancer/102849

Jan 27th, 2023 - The FDA has approved pembrolizumab (Keytruda) as an adjuvant therapy following surgical resection and platinum-based chemotherapy for patients with stage IB, II, or IIIA non-small cell lung cancer (NSCLC), Merck announced. The approval makes pembrolizumab the only immunotherapy to be approved for NSCLC regardless of PD-L1 expression in both the adjuvant and metastatic settings, the company note...

Immunotherapy Survival Gains 'Less Impressive' in Older Lung Cancer Patients
https://www.medpagetoday.com/hematologyoncology/lungcancer/102832

Jan 26th, 2023 - The introduction of immune checkpoint inhibitors (ICIs) for advanced non-small cell lung cancer (NSCLC) in 2015 has resulted in meaningful survival gains for younger patients, but gains were far more modest among older patients, according to a large cohort study. In advanced NSCLC patients under 55, median overall survival (OS) increased on the order of 4.5 months from 2011 to 2019, roughly 4 y...

MDM2 Inhibitor Breaks Through in Trial of Liposarcoma, Other Advanced Malignancies
https://www.medpagetoday.com/hematologyoncology/othercancers/102805

Jan 26th, 2023 - Almost half of patients with advanced solid tumors or lymphomas experienced disease control with a drug that reactivates the TP53 tumor suppressor, a first-in-human study showed. Overall, the oral murine double minute-2 (MDM2) inhibitor milademetan produced a disease control rate (DCR) of 45.8% in 107 patients, including 58.5% in a subgroup with dedifferentiated liposarcomas (DDLPS). Notably, a...

New Class of Factor VIII Replacement Therapy Prevents Bleeds in Severe Hemophilia A
https://www.medpagetoday.com/hematologyoncology/hemophilia/102808

Jan 25th, 2023 - Treatment with investigational efanesoctocog alfa (formerly BIVV001) -- a new class of factor VIII replacement therapy -- prevented bleeding episodes in patients with severe hemophilia A, according to results from the phase III XTEND-1 trial. Among 133 patients, almost all males, who received once-weekly prophylaxis with efanesoctocog alfa 50 IU/kg for 52 weeks (group A), the median annualized ...

Four Germline Mutations Up Risk of Contralateral Breast Cancer
https://www.medpagetoday.com/hematologyoncology/breastcancer/102790

Jan 24th, 2023 - Four pathogenic variants (PVs) in women diagnosed with breast cancer increased the risk of developing cancer in both breasts, according to researchers. Their study of more than 15,000 women who had undergone ipsilateral surgery for invasive breast cancer showed that carriers of germline PVs in BRCA1, BRCA2, and CHEK2 had a roughly two- to threefold higher risk of contralateral breast cancer (CB...

Neoadjuvant Chemo Reduces Disease Recurrence in Operable Colon Cancer
https://www.medpagetoday.com/hematologyoncology/coloncancer/102769

Jan 24th, 2023 - Six weeks of neoadjuvant chemotherapy for patients with operable colon cancer is safe and results in downstaging, increased complete resection rates, and better disease control at 2 years, according to results from the randomized FOxTROT trial. Patients allocated to neoadjuvant chemotherapy followed by 18 weeks of postoperative chemotherapy had a 16.9% risk of residual or recurrent disease with...

Uterine Cancer Recognized as 9/11-Related; Working With Cancer; Post-Dx Suicide Risk
https://www.medpagetoday.com/hematologyoncology/othercancers/102730

Jan 20th, 2023 - The CDC added uterine cancer to the list of covered World Trade Center-related conditions; women enrolled in the World Trade Center Health Program will have access to cancer care and treatment if their uterine cancer is related to 9/11 exposures. A health insurance coding change could limit breast reconstruction options for women with breast cancer. (CBS News) Tennis legend Chris Evert announce...

FDA Greenlights BTK Inhibitor Zanubrutinib for CLL/SLL
https://www.medpagetoday.com/hematologyoncology/leukemia/102724

Jan 20th, 2023 - The FDA has approved the Bruton's tyrosine kinase (BTK) inhibitor zanubrutinib (Brukinsa) for the treatment of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Approval was based on results from the phase III SEQUOIA and ALPINE trials that demonstrated significant efficacy and a favorable safety profile for zanubrutinib in both the first-line and relapsed/re...

FDA OKs First Targeted Treatment for HER2-Positive Colorectal Cancer
https://www.medpagetoday.com/hematologyoncology/coloncancer/102708

Jan 19th, 2023 - The FDA has granted accelerated approval to tucatinib (Tukysa) in combination with trastuzumab (Herceptin) for adult patients with RAS wild-type, HER2-positive unresectable or metastatic colorectal cancer who have progressed following treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, Seagen announced. This is the first FDA-approved treatment for HER2-positive me...

MRI-Guided RT Reduced Acute Toxic Effects in Men With Localized Prostate Cancer
https://www.medpagetoday.com/hematologyoncology/prostatecancer/102686

Jan 18th, 2023 - Stereotactic body radiotherapy (SBRT) guided by MRI for localized prostate cancer resulted in fewer toxicities and an improvement in quality of life compared with CT guidance, according to the randomized phase III MIRAGE trial. At 3-month follow-up, incidence of acute grade 2 or higher genitourinary toxic effects was 24.4% with MRI-guided SBRT versus 43.4% with CT guidance (P=0.01), while incid...

Short-Course Apalutamide to Reduce Active Surveillance Attrition in Prostate Cancer
https://www.medpagetoday.com/hematologyoncology/prostatecancer/102667

Jan 17th, 2023 - A majority of men in active surveillance (AS) for early prostate cancer had negative biopsies after a 90-day course of apalutamide (Erleada), a small phase II trial showed. Follow-up pathology showed no evidence of residual cancer in 13 of 22 evaluable patients following treatment with the androgen receptor inhibitor. The median time to a positive biopsy was 364 days, and the treatment was asso...

Post-Transplant Triplet Bests Lenalidomide Maintenance Alone in Myeloma
https://www.medpagetoday.com/hematologyoncology/myeloma/102665

Jan 17th, 2023 - Use of a triple-drug maintenance combination appeared to improve progression-free survival (PFS) in patients with newly diagnosed multiple myeloma following induction therapy and autologous stem-cell transplantation, an interim analysis of the phase III ATLAS trial suggested. In an intention-to-treat analysis, the median PFS was 59.1 months for patients treated with carfilzomib (Kyprolis), lena...

Off-the-Shelf T-Cell Therapy Effective Against Viral Infections After Allo-HCT
https://www.medpagetoday.com/hematologyoncology/hematology/102638

Jan 13th, 2023 - An investigational, off-the-shelf T-cell therapy appears to be effective against six different viral infections that are common in patients who undergo allogeneic hematopoietic cell transplantation (HCT), according to results from a phase II trial. Posoleucel achieved a partial or complete antiviral response in 95% of 58 adult and pediatric patients infected with one or more of the viruses with...

Rise in Cervical Cancer Mortality; Drug Active in Kids' Glioma; Vit D and Melanoma
https://www.medpagetoday.com/hematologyoncology/cervicalcancer/102634

Jan 13th, 2023 - A California study showed a concerning increase in cervical cancer mortality among women 65 or older, the age at which routine screening is no longer recommended. (UC Davis Comprehensive Cancer Center, Cancer Epidemiology, Biomarkers & Prevention) AstraZeneca will discontinue sales of moxetumomab pasudotox (Lumoxiti) for hairy cell leukemia in the U.S. because of competition and other factors u...

High Response Rate With Neoadjuvant Anti-PD-1 in Localized dMMR Colorectal Cancer
https://www.medpagetoday.com/hematologyoncology/coloncancer/102615

Jan 12th, 2023 - Neoadjuvant immunotherapy with PD-1 inhibitors led to objective responses in 85% of patients with localized and locally advanced colorectal cancer (CRC) with mismatch repair deficiency (dMMR)/high microsatellite instability (MSI-H), a retrospective study from China showed. Overall, 62 of 73 patients achieved objective responses, primarily with single-agent PD-1 inhibition. Response rates were s...